Old Web
English
Sign In
Acemap
>
authorDetail
>
N.E. Wilsher
N.E. Wilsher
Chemistry
Cancer research
MAPK/ERK pathway
anti tumour
Small molecule
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models
2020
European Journal of Cancer
Tomoko Smyth
J. Brothwood
L. Fazal
K. Hearn
C Hindley
C. Johnson
M. Jones
N. Kandola
John Lyons
V. Martins
K. Miyadera
S. Muench
J. Munck
Y. Nakatsuru
H. Ochiiwa
H. Saïni
A. Shah
S. Wagner
N.E. Wilsher
Nicola G. Wallis
Show All
Source
Cite
Save
Citations (0)
Identification of potent small molecule allosteric inhibitors of SHP2
2020
European Journal of Cancer
K. Hearn
V. Berdini
G Chessari
T.G. Davies.
J.E.H. Day
C. Hamlett
S Hiscock
V. Martins
S. Muench
Y. Nakatsuru
H. Ochiiwa
A. Price
Sharna J. Rich
A. Shah
Y. Shibata
T. Shimamura
Tomoko Smyth
Nicola G. Wallis
N.E. Wilsher
C.N. Johnson
Show All
Source
Cite
Save
Citations (0)
The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
2020
European Journal of Cancer
J. Munck
V. Berdini
Aurélie Courtin
C East
T. Heightman
C Hindley
J. Kucia-Tran
John Lyons
V. Martins
S. Muench
Christopher W. Murray
D Norton
M. O'Reilly
M. Reader
David C. Rees
Sharna J. Rich
N. Thompson
N.E. Wilsher
A.J.A. Woolford
Nicola G. Wallis
Show All
Source
Cite
Save
Citations (0)
1